Abstract
Peptide receptor radionuclide therapy (PRRNT) using {sup 90}Y-DOTATOC was first administered in 1996 in Basel, Switzerland, to a 40 year old patient with a gastroenteropancreatic neuroendocrine tumour (NET). The objective was to stabilize the progression of the tumour, which had proven refractory to conventional chemotherapy. The excellent subjective and objective responses after several treatment cycles prompted exhaustive pre-clinical and clinical research to explore the therapeutic potential of PRRNT for the treatment of NETs. Since then, PRRNT using {sup 90}Y- or {sup 177}Lu-DOTATOC has acquired wide acceptance and is now used in many medical centres in Europe and other parts of the world. NET is a unique subclass of cancer in which a good percentage of affected patients may experience disease control following several cycles of PRRNT, with improvement of symptoms and quality of life in the majority of cases. This book is a practical reference for specialists in clinical oncology and nuclear medicine embarking on deploying and executing a comprehensive programme for treating patients with NETs. It is part of a larger endeavour of the IAEA to enable medical centres in Member States to introduce therapeutic applications of unsealed radioisotopes in clinical routine practice. This publication provides comprehensive, multidisciplinary guidance
More>>
Citation Formats
None.
Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) for Neuroendocrine Tumours.
IAEA: N. p.,
2013.
Web.
None.
Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) for Neuroendocrine Tumours.
IAEA.
None.
2013.
"Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) for Neuroendocrine Tumours."
IAEA.
@misc{etde_22102466,
title = {Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) for Neuroendocrine Tumours}
author = {None}
abstractNote = {Peptide receptor radionuclide therapy (PRRNT) using {sup 90}Y-DOTATOC was first administered in 1996 in Basel, Switzerland, to a 40 year old patient with a gastroenteropancreatic neuroendocrine tumour (NET). The objective was to stabilize the progression of the tumour, which had proven refractory to conventional chemotherapy. The excellent subjective and objective responses after several treatment cycles prompted exhaustive pre-clinical and clinical research to explore the therapeutic potential of PRRNT for the treatment of NETs. Since then, PRRNT using {sup 90}Y- or {sup 177}Lu-DOTATOC has acquired wide acceptance and is now used in many medical centres in Europe and other parts of the world. NET is a unique subclass of cancer in which a good percentage of affected patients may experience disease control following several cycles of PRRNT, with improvement of symptoms and quality of life in the majority of cases. This book is a practical reference for specialists in clinical oncology and nuclear medicine embarking on deploying and executing a comprehensive programme for treating patients with NETs. It is part of a larger endeavour of the IAEA to enable medical centres in Member States to introduce therapeutic applications of unsealed radioisotopes in clinical routine practice. This publication provides comprehensive, multidisciplinary guidance on the use of PRRNT in order to enhance the effective, safe and standardized implementation of best practice for treating patients with NETs and gastroenteropancreatic cancers, with due regard to the recent international classifications of NETs. It provides comprehensive protocols for employing either {sup 90}Y or {sup 177}Lu tagged somatostatin receptor targeting peptides, as well as clinically assessed protocols for renal protection. It is a comprehensive compilation of clinically based evidence with input from experienced and renowned medical professionals in this field. The various sections cover clinical presentations, patient eligibility criteria and means of assessing the effectiveness of therapy utilizing molecular and morphological medical imaging techniques. The decision of whether or not to prescribe PRRNT is to be made by the treating medical physicians after considering histological reports, anatomical and functional imaging, previous therapeutic regimens, cumulative irradiation dose to critical organs and existing risk factors in susceptible patients. In selected patients, however, it may be appropriate for the conscientious physician to adopt a treatment strategy different from that set out in this book, tailored to the condition of the patient or governed by other circumstances such as the availability of radiopharmaceuticals or advances in knowledge made since the publication of this guidance. The IAEA wishes to acknowledge the many individuals who contributed to and reviewed this manuscript for sharing their invaluable knowledge and time, and for their efforts to achieve a consensus on the guidance provided here. The IAEA officer responsible for this publication was J.J. Zaknun of the Division of Human Health.}
place = {IAEA}
year = {2013}
month = {Mar}
}
title = {Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) for Neuroendocrine Tumours}
author = {None}
abstractNote = {Peptide receptor radionuclide therapy (PRRNT) using {sup 90}Y-DOTATOC was first administered in 1996 in Basel, Switzerland, to a 40 year old patient with a gastroenteropancreatic neuroendocrine tumour (NET). The objective was to stabilize the progression of the tumour, which had proven refractory to conventional chemotherapy. The excellent subjective and objective responses after several treatment cycles prompted exhaustive pre-clinical and clinical research to explore the therapeutic potential of PRRNT for the treatment of NETs. Since then, PRRNT using {sup 90}Y- or {sup 177}Lu-DOTATOC has acquired wide acceptance and is now used in many medical centres in Europe and other parts of the world. NET is a unique subclass of cancer in which a good percentage of affected patients may experience disease control following several cycles of PRRNT, with improvement of symptoms and quality of life in the majority of cases. This book is a practical reference for specialists in clinical oncology and nuclear medicine embarking on deploying and executing a comprehensive programme for treating patients with NETs. It is part of a larger endeavour of the IAEA to enable medical centres in Member States to introduce therapeutic applications of unsealed radioisotopes in clinical routine practice. This publication provides comprehensive, multidisciplinary guidance on the use of PRRNT in order to enhance the effective, safe and standardized implementation of best practice for treating patients with NETs and gastroenteropancreatic cancers, with due regard to the recent international classifications of NETs. It provides comprehensive protocols for employing either {sup 90}Y or {sup 177}Lu tagged somatostatin receptor targeting peptides, as well as clinically assessed protocols for renal protection. It is a comprehensive compilation of clinically based evidence with input from experienced and renowned medical professionals in this field. The various sections cover clinical presentations, patient eligibility criteria and means of assessing the effectiveness of therapy utilizing molecular and morphological medical imaging techniques. The decision of whether or not to prescribe PRRNT is to be made by the treating medical physicians after considering histological reports, anatomical and functional imaging, previous therapeutic regimens, cumulative irradiation dose to critical organs and existing risk factors in susceptible patients. In selected patients, however, it may be appropriate for the conscientious physician to adopt a treatment strategy different from that set out in this book, tailored to the condition of the patient or governed by other circumstances such as the availability of radiopharmaceuticals or advances in knowledge made since the publication of this guidance. The IAEA wishes to acknowledge the many individuals who contributed to and reviewed this manuscript for sharing their invaluable knowledge and time, and for their efforts to achieve a consensus on the guidance provided here. The IAEA officer responsible for this publication was J.J. Zaknun of the Division of Human Health.}
place = {IAEA}
year = {2013}
month = {Mar}
}